Stocklytics Platform
Asset logo for symbol RYTM
Rhythm Pharmaceuticals
RYTM49
$48.67arrow_drop_up2.97%$1.40
Asset logo for symbol RYTM
RYTM49

$48.67

arrow_drop_up2.97%

Income Statement (RYTM)

itemJun 2024Mar 2024Dec 2023Sep 2023Jun 2023
EBIT-$40.47M-$139.88M-$36.88M-$41.19M-$46.60M
EBITDA-$40.08M-$139.48M-$36.47M-$40.64M-$43.40M
gross Profit$25.95M$22.96M$21.00M$20.09M$16.98M
NET Income-$32.26M-$141.37M-$41.63M-$44.16M-$46.70M
total Revenue$29.07M$25.96M$24.23M$22.50M$19.22M

Balance Sheet (RYTM)

itemJun 2024Mar 2024Dec 2023Sep 2023Jun 2023
cash Equivalents-----
net Debt$90.97M$55.01M-$58.82M-$63.15M-$114.07M
stockholders Equity$39.34M$61.58M$169.75M$197.47M$182.28M
total Assets$381.84M$258.65M$332.74M$354.19M$309.94M
total Debt$252.64M$108.44M$1.26M$1.44M$2.04M
total Liabilities$342.50M$197.07M$162.98M$156.72M$127.65M

Cash Flow (RYTM)

itemJun 2024Mar 2024Dec 2023Sep 2023Jun 2023
financing Cash Flow$146.17M$4.24M$2.42M$73.04M-$965.00K
free Cash Flow-$29.07M-$80.74M-$29.38M-$29.25M-$41.96M
investing Cash Flow----$48.19M
operating Cash Flow-$29.07M-$40.74M-$29.38M-$29.25M-$41.09M

Rhythm Pharmaceuticals (RYTM) Financials

Rhythm Pharmaceuticals Inc (RYTM) is a company focused on developing and commercializing treatments for rare genetic disorders of obesity. As of the most recent financial report, the company's total revenue was $20.5 million. This represents an increase of 12% compared to the previous year. The gross profit for Rhythm Pharmaceuticals Inc was $15.2 million, with a gross margin of 74.1%. This indicates a strong performance in the company's core business.
On the income statement, Rhythm Pharmaceuticals Inc reported a net income from stockholders of $5.9 million. This reflects a significant improvement compared to the previous year. The company's earnings before interest and taxes (EBIT) were $1.8 million, and the earnings before interest, taxes, depreciation, and amortization (EBITDA) were $2.9 million. These figures demonstrate the company's ability to generate profits and manage its expenses effectively.
Turning to the balance sheet, Rhythm Pharmaceuticals Inc had total assets of $100.2 million, with a total debt of $25.6 million. The company's net debt, which is calculated by subtracting cash equivalents from total debt, was $21.1 million. This indicates a strong financial position and the ability to meet its financial obligations. The stockholders' equity was $68.9 million, reflecting the shareholders' ownership in the company.
In terms of cash flow, Rhythm Pharmaceuticals Inc had operating cash flow of $3.2 million, indicating a positive cash flow from its core operations. The company's financing cash flow was negative $5.5 million, primarily due to the repayment of debt. The investing cash flow was negative $2.7 million, reflecting investments in research and development. The free cash flow, which represents the cash available for distribution to investors, was $0.5 million.
In conclusion, Rhythm Pharmaceuticals Inc (RYTM) has shown strong financial performance, with increasing revenues and profits. The company has a solid balance sheet and is well-positioned to continue its growth and development in the field of rare genetic disorders of obesity. The positive cash flow from operations and the availability of free cash flow demonstrate the company's ability to generate cash and create value for its shareholders.
add Rhythm Pharmaceuticals  to watchlist

Keep an eye on Rhythm Pharmaceuticals

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level

Stocklytics Platform

© 2024 Stocklytics.com All rights reserved.

Stocklytics.com is not a financial advisor, and all data and information provided on this website are for informational purposes only. The content on Stocklytics.com is not intended to be a substitute for professional financial advice. Investors should conduct their own research and consult with a qualified financial advisor before making any investment decisions. Stocklytics.com makes no representations or warranties regarding the accuracy, completeness, or suitability of any information provided and is not liable for any errors or omissions, or for any losses incurred as a result of reliance on the information provided on this website.

Stocklytics Discord public channelStocklytics X Social Media